Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash & Equivalents (2016 - 2025)

Fennec Pharmaceuticals' Cash & Equivalents history spans 15 years, with the latest figure at $36.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 38.12% year-over-year to $36.8 million, compared with a TTM value of $36.8 million through Dec 2025, up 38.12%, and an annual FY2025 reading of $36.8 million, up 38.12% over the prior year.
  • Cash & Equivalents for Q4 2025 was $36.8 million at Fennec Pharmaceuticals, up from $21.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $51.2 million in Q1 2024, with the low at $12.4 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $25.3 million, with a median of $23.8 million recorded in 2022.
  • Year-over-year, Cash & Equivalents crashed 58.33% in 2023 and then surged 285.74% in 2024.
  • Tracing FENC's Cash & Equivalents over 5 years: stood at $24.3 million in 2021, then decreased by 2.31% to $23.8 million in 2022, then crashed by 44.19% to $13.3 million in 2023, then surged by 100.72% to $26.6 million in 2024, then soared by 38.12% to $36.8 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Cash & Equivalents are $36.8 million (Q4 2025), $21.9 million (Q3 2025), and $18.7 million (Q2 2025).